The Society of Hematologic Oncology (SOHO) was established as a non-profit corporation in 2012 with aims to promote worldwide research, education, prevention, clinical studies and optimal patient care in all aspects of hematologic malignancies and related disorders.
A phase 3 study is assessing a measurable residual disease (MRD)-driven consolidation and maintenance strategy for patients with newly diagnosed multiple myeloma (NDMM).
In this editorial, SOHO Insider Associate Editor Dr. Jerry Radich draws a parallel between cancer treatment and agricultural pest control.
A small phase 1 study published in The New England Journal of Medicine found that the investigational anti-CD19 armored chimeric antigen receptor (CAR)
The US Food and Drug Administration (FDA) will review a supplemental Biologics License Application (sBLA) for epcoritamab combined with rituximab and lenalidomide (R2)
Presession focused on MDS/MPN-related anemia. Participants can register for the presession and SOHO 2025 at soho.click/2025 . HOUSTON, April 3, 2025 /PRNewswire/ — The Society of Hematologic Oncology
An Italian real-world study assessed the use of asciminib in a compassionate use setting in heavily pretreated patients with chronic-phase chronic myeloid leukemia
The Center for Drug Evaluation (CDE) of the China National Medical Products Administration (NMPA) has granted Breakthrough Therapy Designation for mesutoclax for the
The US Food and Drug Administration (FDA) has granted Orphan Drug Designation for bexmarilimab for the treatment of patients with myelodysplastic syndromes (MDS).
A phase 1b/2 study found that the combination of azacitidine, venetoclax, and magrolimab was safe for the treatment of acute myeloid leukemia (AML),
Cord blood-derived natural killer (NK) cells pre-complexed with AFM13, a CD30/CD16A bispecific antibody, resulted in 2-year event-free and overall survival rates of 26.2%
